公开(公告)号：US09616138B1

公开(公告)日：2017-04-11

申请号：US14498988

申请日：2014-09-26

Applicant: Raul Iglesias ,  Piyush Koria

Inventor： Raul Iglesias ,  Piyush Koria

IPC: A61K38/00 ,  A61K47/48 ,  C07K14/475 ,  A61K38/18 ,  A61K38/10 ,  C07K14/485 ,  C07K14/78

CPC classification number: A61K47/48292 ,  A61K38/10 ,  A61K38/1825 ,  C07K14/475 ,  C07K14/485 ,  C07K14/78 ,  C07K2319/10 ,  C07K2319/33 ,  C07K2319/735

Abstract: Disclosed herein are cargo carrying nanoparticles and pharmaceutical formulations thereof. The cargo carrying nanoparticles can self-assemble from cargo molecule subunits and/or targeting subunits. The cargo carrying molecules can be configured to induce macropinocytosis in a cell when a targeting moiety specifically binds a binding partner on the surface of a cell. The pharmaceutical formulations containing the cargo carrying nanoparticles disclosed herein can be administered to a patient for the treatment or prevention of cancer.

公开(公告)号：US5686059A

公开(公告)日：1997-11-11

申请号：US462128

申请日：1995-06-05

Applicant: Paul F. Goetinck ,  Mehrdad Tondravi

Inventor： Paul F. Goetinck ,  Mehrdad Tondravi

IPC: C12N15/09 ,  A61K38/00 ,  A61K47/48 ,  A61K49/00 ,  A61K51/08 ,  A61P43/00 ,  C07K14/47 ,  C07K14/78 ,  C12N1/21 ,  C12N15/12 ,  C12P21/02 ,  C12R1/19 ,  A61K38/06 ,  A61K38/17 ,  C07K1/00

CPC classification number: A61K47/48292 ,  A61K47/48307 ,  C07K14/78 ,  A61K38/00 ,  C07K2319/00

Abstract: DNA constructs coding for a chimeric polypeptides containing fragments of cartilage matrix proteins that can bind collagen and their protein products are described. Also, the invention relates to purified chimeric polypeptides, and methods of their production and purification from transformed cells as well as their use as agents in therapeutics and clinical imaging. In addition, the invention disclosed a method for forming collagen fibrils using the chimeric polypeptide.

Abstract translation: 描述了编码含有可结合胶原及其蛋白质产物的软骨基质蛋白片段的嵌合多肽的DNA构建体。 此外，本发明涉及纯化的嵌合多肽，以及它们从转化细胞产生和纯化的方法以及它们作为治疗剂和临床成像中的试剂的用途。 此外，本发明公开了使用嵌合多肽形成胶原纤维的方法。

公开(公告)号：US5446091A

公开(公告)日：1995-08-29

申请号：US368874

申请日：1995-01-05

Applicant: Woonza Rhee ,  Donald G. Wallace ,  Alan S. Michaels ,  Ramon A. Burns, Jr. ,  Louis Fries ,  Frank DeLustro ,  Hanne Bentz

Inventor： Woonza Rhee ,  Donald G. Wallace ,  Alan S. Michaels ,  Ramon A. Burns, Jr. ,  Louis Fries ,  Frank DeLustro ,  Hanne Bentz

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/06 ,  A61K38/00 ,  A61K38/17 ,  A61K38/21 ,  A61K38/22 ,  A61K45/06 ,  A61K47/48 ,  A61L15/22 ,  A61L24/10 ,  A61L26/00 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/04 ,  A61L29/06 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/12 ,  A61P17/00 ,  A61P43/00 ,  C07K14/495 ,  C07K14/78 ,  C08B37/08 ,  C08G81/00 ,  C08H1/00 ,  C08H1/06 ,  C08L89/00 ,  C08L89/06 ,  C09J189/06 ,  G02B1/04 ,  C08G63/48 ,  C08G63/91

CPC classification number: C08L89/06 ,  A61K47/48215 ,  A61K47/4823 ,  A61K47/48292 ,  A61L15/225 ,  A61L24/102 ,  A61L26/0033 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/043 ,  A61L29/045 ,  A61L29/06 ,  A61L29/16 ,  A61L31/041 ,  A61L31/042 ,  A61L31/044 ,  A61L31/10 ,  A61L31/125 ,  C07K14/495 ,  C07K14/78 ,  C08B37/0069 ,  C08B37/0072 ,  C08H1/06 ,  C09J189/06 ,  G02B1/043 ,  A61F2/07 ,  A61F2310/00365 ,  A61K38/00 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/62 ,  A61L2300/802 ,  A61L2430/16 ,  Y10S525/937

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living being for the purpose of providing soft tissue augmentation. Once in place, the particles rehydrate and expand in size five fold or more.

Abstract translation: 药学上可接受的非免疫原性组合物通过经由特定类型的化学键共价结合肽肽胶原与药学​​纯合成的亲水性聚合物形成，以提供胶原/聚合物共轭物。 糖尿病胶原可以是I型，II型或III型，并且可以是纤维状或非纤维状的。 合成亲水性聚合物可以是重均分子量在约100至约20,000范围内的聚乙二醇及其衍生物。 组合物可以包括其它组分，例如液体，药学上可接受的，载体以形成可注射制剂，和/或生物活性蛋白质例如生长因子。 当形成时，本发明的胶原 - 聚合物共轭物通常含有大量的水。 可以将共轭物脱水形成相对固体的物体。 脱水的固体可以被研磨成可以悬浮在诸如油之类的非水性流体中的颗粒，并注入活体以提供软组织增加。 一旦就位，颗粒再水合并扩大五倍以上。

公开(公告)号：US5324775A

公开(公告)日：1994-06-28

申请号：US907518

申请日：1992-07-02

Applicant: Woonza Rhee ,  Donald G. Wallace ,  Alan S. Michaels ,  Ramon A. Burns, Jr. ,  Louis Fries ,  Frank DeLustro ,  Hanne Bentz

Inventor： Woonza Rhee ,  Donald G. Wallace ,  Alan S. Michaels ,  Ramon A. Burns, Jr. ,  Louis Fries ,  Frank DeLustro ,  Hanne Bentz

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/06 ,  A61K38/00 ,  A61K38/17 ,  A61K38/21 ,  A61K38/22 ,  A61K45/06 ,  A61K47/48 ,  A61L15/22 ,  A61L24/10 ,  A61L26/00 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/04 ,  A61L29/06 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/12 ,  A61P17/00 ,  A61P43/00 ,  C07K14/495 ,  C07K14/78 ,  C08B37/08 ,  C08G81/00 ,  C08H1/00 ,  C08H1/06 ,  C08L89/00 ,  C08L89/06 ,  C09J189/06 ,  G02B1/04 ,  C08G63/48 ,  C08G63/91 ,  C08G63/40

CPC classification number: C08L89/06 ,  A61K47/48215 ,  A61K47/4823 ,  A61K47/48292 ,  A61L15/225 ,  A61L24/102 ,  A61L26/0033 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/043 ,  A61L29/045 ,  A61L29/06 ,  A61L29/16 ,  A61L31/041 ,  A61L31/042 ,  A61L31/044 ,  A61L31/10 ,  A61L31/125 ,  C07K14/495 ,  C07K14/78 ,  C08B37/0069 ,  C08B37/0072 ,  C08H1/06 ,  C09J189/06 ,  G02B1/043 ,  A61F2/07 ,  A61F2310/00365 ,  A61K38/00 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/62 ,  A61L2300/802 ,  A61L2430/16 ,  Y10S525/937

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding biologically inactive, natural, biocompatible polymer to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide biocompatible conjugates. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living (preferably human) being for the purpose of providing soft tissue augmentation. Once in place, the particles rehydrate and expand in size five fold or more.

Abstract translation: 药学上可接受的非免疫原性组合物通过经由特定类型的化学键共价结合生物活性的，天然的，生物相容的聚合物与药学纯的，合成的，亲水的聚合物形成，以提供生物相容的共轭物。 合成亲水性聚合物可以是重均分子量在约100至约20,000范围内的聚乙二醇及其衍生物。 组合物可以包括其它组分，例如液体，药学上可接受的，载体以形成可注射制剂，和/或生物活性蛋白质例如生长因子。 当形成时，本发明的共轭物通常含有大量的水。 可以将共轭物脱水形成相对固体的物体。 脱水的固体物体可以研磨成可以悬浮在非水性流体例如油中的颗粒，并且注入到生物（优选人）中，以提供软组织增加。 一旦就位，颗粒再水合并扩大五倍以上。

公开(公告)号：US08946163B2

公开(公告)日：2015-02-03

申请号：US13815834

申请日：2013-03-15

Applicant: MiMedx Group, Inc.

Inventor： Thomas J. Koob

IPC: A61K47/48

CPC classification number: A61K47/48292 ,  A61K31/282 ,  A61K31/555 ,  A61K33/24 ,  A61K47/6435 ,  A61K47/6953 ,  C07K14/78 ,  C12N2533/54

Abstract: The disclosure describes collagen constructs comprising anticancer agents, preferably, platinum, and related methods.

Abstract translation: 本公开描述了包含抗癌剂，优选铂的胶原构建体和相关方法。

公开(公告)号：US20140142025A1

公开(公告)日：2014-05-22

申请号：US13815736

申请日：2013-03-15

Applicant: MiMedx Group, Inc.

Inventor： Thomas J. Koob

IPC: A61K47/48 ,  A61K9/00

CPC classification number: A61K47/48292 ,  A61K8/19 ,  A61K8/65 ,  A61K9/0024 ,  A61K33/38 ,  A61K38/39 ,  A61K47/42 ,  A61K47/6435 ,  A61K2800/51 ,  A61L27/24 ,  A61L27/54 ,  A61L2300/104 ,  A61L2300/404 ,  A61Q17/005 ,  A61K2300/00

Abstract: The disclosure describes collagen constructs comprising antimicrobial agents and related methods.

Abstract translation: 本公开描述了包含抗微生物剂和相关方法的胶原构建体。

公开(公告)号：US5972707A

公开(公告)日：1999-10-26

申请号：US890599

申请日：1997-07-09

Applicant: Krishnendu Roy ,  Hai-Quan Mao ,  Vu L. Truong ,  Thomas August ,  Kam W. Leong

Inventor： Krishnendu Roy ,  Hai-Quan Mao ,  Vu L. Truong ,  Thomas August ,  Kam W. Leong

IPC: C12N15/09 ,  A61K9/16 ,  A61K9/51 ,  A61K47/48 ,  A61K48/00 ,  C12N15/88 ,  C12N15/00

CPC classification number: A61K9/5161 ,  A61K47/4823 ,  A61K47/48238 ,  A61K47/48292 ,  A61K47/48561 ,  A61K47/48876 ,  A61K9/167 ,  A61K9/5169 ,  A61K9/5192 ,  B82Y5/00 ,  C12N15/88 ,  A61K48/00 ,  Y10S977/808 ,  Y10S977/906 ,  Y10S977/915 ,  Y10S977/916 ,  Y10S977/92

Abstract: A gene delivery system is made of enzymatically degradable polymeric cation and nucleic acid (DNA or RNA) nanospheres optionally with a linking moiety or a targeting ligand attached to the surface. The delivery system can be made by a simple method of coacervation. Targeting ligands can be attached to the nanosphere directly or via a linking moiety. The linkage design allows the attachment of any molecule onto the nanosphere surface including antibodies, cell adhesion molecules, hormones and other cell-specific ligands.

Abstract translation: 基因递送系统由可酶降解的聚合阳离子和核酸（DNA或RNA）纳米球制成，任选地具有连接部分或连接到表面的靶向配体。 输送系统可以通过简单的凝聚方法制成。 靶向配体可以直接或通过连接部分连接到纳米球。 连接设计允许将任何分子附着到纳米球表面，包括抗体，细胞粘附分子，激素和其他细胞特异性配体。

公开(公告)号：US5731409A

公开(公告)日：1998-03-24

申请号：US330599

申请日：1994-10-28

Applicant: Gregg B. Fields ,  Leo T. Furcht ,  James B. McCarthy

Inventor： Gregg B. Fields ,  Leo T. Furcht ,  James B. McCarthy

IPC: A61K47/48 ,  C07K14/78 ,  A61K38/00 ,  C07K1/00 ,  C07K5/00 ,  C07K7/00

CPC classification number: A61K47/48292 ,  C07K14/78

Abstract: Polypeptides are provided that have a sequence of at least about four amino acids corresponding substantially to an amino acid sequence within the triple-helical domain of Type I collagen. The polypeptides promote cell adhesion and/or cell migration. Cell culture substrates coated with the polypeptides are also provided. Prosthetic devices and methods for identifying and distinguishing cells of different types are also provided.

Abstract translation: 提供多肽，其具有至少约四个氨基酸的序列，其基本上对应于I型胶原的三螺旋结构域内的氨基酸序列。 多肽促进细胞粘附和/或细胞迁移。 还提供了用多肽包被的细胞培养物底物。 还提供了用于识别和区分不同类型的细胞的假体装置和方法。

公开(公告)号：US5693341A

公开(公告)日：1997-12-02

申请号：US405320

申请日：1995-03-16

Applicant: Jacqueline A. Schroeder ,  Hanne Bentz ,  Trudy D. Estridge

Inventor： Jacqueline A. Schroeder ,  Hanne Bentz ,  Trudy D. Estridge

IPC: A61K47/42 ,  A61K47/48 ,  A61K47/36 ,  A61K97/42

CPC classification number: A61K47/48292 ,  Y10S514/801

Abstract: Affinity bound collagen matrices for the delivery of biologically active agents, and methods for preparing such matrices, are disclosed. A preferred method for preparing the matrices of the invention comprises mixing a binding ligand and an active agent together, allowing the resulting binding ligand-active agent mixture to form an affinity bound complex, then combining the resulting affinity bound complex with collagen to form a matrix. Particular affinity bound matrices comprising collagen, heparin, and an active agent are also disclosed, as well as methods for using the matrices of the invention for delivery of biologically active agents.

Abstract translation: 公开了用于递送生物活性剂的亲和结合胶原基质和制备这种基质的方法。 用于制备本发明的基质的优选方法包括将结合配体和活性剂混合在一起，使所得的结合配体 - 活性剂混合物形成亲和结合的复合物，然后将所得的亲和结合复合物与胶原组合以形成基质 。 还公开了包含胶原，肝素和活性剂的特定的亲和力结合基质，以及使用本发明的基质递送生物活性剂的方法。

公开(公告)号：US5298243A

公开(公告)日：1994-03-29

申请号：US422701

申请日：1989-10-17

Applicant: Yoshito Ikada ,  Yasuhiko Tabata ,  Hiroyasu Suzuki

Inventor： Yoshito Ikada ,  Yasuhiko Tabata ,  Hiroyasu Suzuki

IPC: A61K38/19 ,  A61K47/48 ,  C07K15/00 ,  C07K3/02

CPC classification number: A61K38/193 ,  A61K47/48292

Abstract: Disclosed are a crosslinked gelatin microspheres containing CSF and a water soluble CSF-gelatin conjugate. Both the microspheres and the water soluble conjugate provide an improved CSF stability. They have a high potentiation on the antitumor activity of macrophages in respect of the CSF amount and the time required for macrophage activation and are effective in maintaining their activated state for a long period, compared with the native CSF. The mechanism of macrophage activation by the microspheres containing CSF is mediated via phagocytosis and different from that by native CSF, which is believed to activate macrophages via cell surface receptor. The species specificity of CSF may be abrogated when the CSF is internalized into macrophages through phagocytosis.

Abstract translation: 公开了含有CSF和水溶性CSF-明胶缀合物的交联明胶微球。 微球和水溶性缀合物都能提供改善的CSF稳定性。 与天然CSF相比，它们对于巨噬细胞的CSF量和巨噬细胞活化所需的时间对抗巨噬细胞的抗肿瘤活性具有高增强作用，并且与天然CSF相比长效保持其活化状态是有效的。 通过含有CSF的微球的巨噬细胞活化的机制是通过吞噬作用介导的，不同于被认为通过细胞表面受体激活巨噬细胞的天然CSF。 当CSF通过吞噬作用内化于巨噬细胞时，CSF的物种特异性可能被消除。